Luminex (NASDAQ: LMNX) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.
Luminex pays an annual dividend of $0.24 per share and has a dividend yield of 1.1%. Dynatronics does not pay a dividend. Luminex pays out 36.4% of its earnings in the form of a dividend.
This table compares Luminex and Dynatronics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a breakdown of recent recommendations and price targets for Luminex and Dynatronics, as provided by MarketBeat.
||Strong Buy Ratings
Luminex presently has a consensus price target of $19.33, suggesting a potential downside of 8.93%. Given Luminex’s higher probable upside, equities research analysts clearly believe Luminex is more favorable than Dynatronics.
Earnings & Valuation
This table compares Luminex and Dynatronics’ top-line revenue, earnings per share and valuation.
||Earnings Per Share
Luminex has higher revenue and earnings than Dynatronics. Dynatronics is trading at a lower price-to-earnings ratio than Luminex, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
79.3% of Luminex shares are owned by institutional investors. Comparatively, 18.2% of Dynatronics shares are owned by institutional investors. 6.9% of Luminex shares are owned by insiders. Comparatively, 51.8% of Dynatronics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Luminex has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Dynatronics has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500.
Luminex beats Dynatronics on 11 of the 13 factors compared between the two stocks.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.
Dynatronics Corporation is a manufacturer and distributor of physical medicine products. The Company’s products include a line of medical equipment for physical medicine applications, including therapy devices, medical supplies and soft goods, treatment tables and rehabilitation equipment. Its products are used by physical therapists, chiropractors, sports medicine practitioners, podiatrists, physicians and other physical medicine professionals. Its physical medicine products include therapeutic modalities, such as Dynatron Solaris, including electrotherapy and thermal therapy, and 25 Series, including electrotherapy and ultrasound; manufactured capital products, including traction systems and wood furniture; manufactured supplies, including cold packs, straps, wedges, bolsters and mats; distributed capital products, including hydrotherapy, weight training equipment and pilates, and distributed supplies, including clinical accessories, sports med and taping products, lotions and gels.
Receive News & Ratings for Luminex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Co. and related companies with MarketBeat.com's FREE daily email newsletter.